Endpoint Named A Leader In Everest Group's 2025 Life Sciences RTSM Products PEAK Matrix Assessment

Recognition as a leader in a rigorous, six-month evaluation of RTSM providers underscores both strategic clarity and consistent execution. This distinction reflects not only strong platform capabilities, but also the trust sponsors place in a partner that continuously evolves to meet complex trial demands. Investments in next-generation technologies, including advanced platforms like Elocity and the integration of AI, are driving measurable improvements in efficiency and scalability across operations.

Rather than a final milestone, this achievement signals momentum—an opportunity to further refine performance, deepen collaboration, and deliver even greater value to sponsors and partners. Ongoing innovation and responsiveness remain central to strengthening outcomes in an increasingly dynamic clinical landscape.

Explore how these advancements are shaping the future of RTSM and driving meaningful progress across clinical trials.